查看文章

It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients with hematologic malignancies [1, 2]. The mRNA-based vaccines BNT162b2 (Pfizer) and mRNA-1273 (Moderna), and adenovirus-based Ad26. COV2. S (Johnson & Johnson) vaccine has robust safety and efficacy against COVID-19 among immunocompetent individuals, however, patients with cancer were not enrolled in these registration trials [3-5]. Emerging evidence suggests that despite the three COVID-19 vaccines with emergency use authorization (EUA) by the FDA inducing high levels of immunity in the general population, patients with hematologic malignancies have lower rates of seroconversion for the SARS-CoV-2 Spike IgG antibody (Spike IgG) and thus possibly lower protection against severe COVID-19 [6-8]. In particular, smaller subgroups of patients with certain hematologic malignancies including chronic …